What's in David H. Canaday's pipeline?

David H. Canaday has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with David H. Canaday's portfolio?

Top competitors by shared drug class: Korea University Guro Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/david-h-canaday.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

David H. Canaday — Portfolio Competitive Intelligence Brief

David H. Canaday pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fluzone HD Vaccine	Fluzone HD Vaccine	marketed
Fluad Vaccine	Fluad Vaccine	marketed	Inactivated influenza vaccine with adjuvant		Immunology / Infectious Disease

Therapeutic area mix

Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Korea University Guro Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for David H. Canaday:

Cite this brief

Drug Landscape (2026). David H. Canaday — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/david-h-canaday. Accessed 2026-05-14.